Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T15:41:45.212Z.
Calculation as of: 2026-10-06T15:41:45.212Z.
Quote observation: 2026-10-06T15:39:32.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5ff4a69d5e0bd829addfa263bba904bf87580f902e4d2830b11cef9910c58a28
PEG RATIO
N/A
Entera Bio Ltd.
Market Cap
$127.66M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Entera Bio Ltd. (ENTX) | $127.66M | N/A |
| Health Catalyst, Inc. (HCAT)vs › | $129.68M | N/A |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $125.34M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $123.17M | N/A |
| Cibus, Inc. (CBUS)vs › | $122.13M | N/A |
| Organigram Global Inc. (OGI)vs › | $132.74M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $121.63M | N/A |
| LifeMD, Inc. (LFMD)vs › | $135.17M | N/A |
| Freenome, Inc. (FRNM)vs › | $136.06M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.99M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
